Nabriva Therapeutics plc Annual Net Income (Loss) Attributable to Parent in USD from 2014 to 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Nabriva Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2014 to 2022.
  • Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2023 was -$12.1M, a 8.92% decline year-over-year.
  • Nabriva Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2023 was -$55.1M, a 18.1% decline year-over-year.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$57.2M, a 15.6% decline from 2021.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$49.5M, a 28.8% increase from 2020.
  • Nabriva Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2020 was -$69.5M, a 16% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$57.2M -$7.74M -15.6% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 -$49.5M +$20M +28.8% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 -$69.5M +$13.3M +16% Jan 1, 2020 Dec 31, 2020 10-K 2023-04-17
2019 -$82.8M +$32M +27.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
2018 -$115M -$40.4M -54.4% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-11
2017 -$74.4M -$19.5M -35.5% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$54.9M -$7.93M -16.9% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
2015 -$47M -$32.7M -230% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-16
2014 -$14.2M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.